Pro- and anti-arrhythmic effects of anti-inflammatory drugs

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2013, Pages 83-93

  Granier, Mathieu ^a,b   Massin, François ^a   Pasquié, Jean Luc ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF MONTPELLIER   (France)

Author keywords

AF ablation; Anti inflammatory; Atrial fibrillation; Colchicine; Corticosteroid; NSAID; Supra ventricular arrhythmias; Ventricular arrhythmia; Ventricular tachycardia

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CALCIUM; CELECOXIB; COLCHICINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; EPLERENONE; GLUCOCORTICOID; GROWTH FACTOR; HYDROCORTISONE; IBUPROFEN; KETOROLAC; MATRIX METALLOPROTEINASE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; REACTIVE OXYGEN METABOLITE; ROFECOXIB; SPIRONOLACTONE;

ALLERGIC DISEASE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY BYPASS GRAFT; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART AUTOMATICITY; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; META ANALYSIS (TOPIC); MYOCARDITIS; NEPHROTOXICITY; NONHUMAN; PAIN; PERICARDITIS; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REENTRY ARRHYTHMIA; REVIEW; RHEUMATIC DISEASE;

ADRENAL CORTEX HORMONES; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; COLCHICINE; HUMANS; TREATMENT OUTCOME;

EID: 84875833436     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/1871523011312010010     Document Type: Review

References (80)

1. Huikuri, H.V.; Castellanos, A.; Myerburg, R.J. Sudden death due to cardiac arrhythmias. N. Engl. J. Med., 2001, 345, 1473-1482.
2. Kirchhof, P.; Auricchio, A.; Bax, J.; Crijns, H.; Camm, J.; Diener, H.; Goette, A.; Hindricks, G.; Hohnloser, S.; Kappenberger, L.; Kuck, K.; Lip, G.; Olsson, B.; Meinertz, T.; Priori, S.; Ravens, U.; Steinbeck, G.; Svernhage, E.; Tijssen, J.; Vincent, A.; Breithardt, G. Outcome parameters for trials in atrial fibrillation: Executive summary. Eur. Heart J., 2007, 28, 2803-2817.
3. Schotten, U.; Verheule, S.; Kirchhof, P.; Goette, A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol. Rev., 2011, 91, 265-325.
4. Friedrichs, K.; Klinke, A.; Baldus, S. Inflammatory pathways underlying atrial fibrillation. Trends Mol. Med., 2011, 17, 556-563.
5. Lacolley, P. Biologie et pathologie du coeur et des vaisseaux; John Libbey Eurotext, 2007.
6. Greiser, M.; Lederer, W. J.; Schotten, U. Alterations of atrial Ca2+ handling as cause and consequence of atrial fibrillation. Cardiovasc. Res., 2011, 89, 722-733.
7. Ryu, K.; Li, L.; Khrestian, C. M.; Matsumoto, N.; Sahadevan, J.; Ruehr, M.L.; Van Wagoner, D.R.; Efimov, I. R.; Waldo, A.L. Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H1231-1241.
8. Lindsey, M.L.; Escobar, G.P.; Mukherjee, R.; Goshorn, D.K.; Sheats, N.J.; Bruce, J.A.; Mains, I.M.; Hendrick, J.K.; Hewett, K.W.; Gourdie, R. G.; Matrisian, L.M.; Spinale, F. G. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation, 2006, 113, 2919-2928.
9. Boos, C.J.; Anderson, R.A.; Lip, G.Y. H. Is atrial fibrillation an inflammatory disorder? Euro. Heart J., 2006, 27, 136-149.
10. Frustaci, A.; Chimenti, C.; Bellocci, F.; Morgante, E.; Russo, M.A.; Maseri, A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 1997, 96, 1180-1184.
11. Chen, M.-C.; Chang, J.-P.; Liu, W.-H.; Yang, C.-H.; Chen, Y.-L.; Tsai, T.-H.; Wang, Y.-H.; Pan, K.-L. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. Am. J. Cardiol., 2008, 102, 861-865.
12. Pagé, P.L.; Plumb, V.J.; Okumura, K.; Waldo, A.L. A new animal model of atrial flutter. J. Am. Coll. Cardiol., 1986, 8, 872-879.
13. Lau, D.H.; Mackenzie, L.; Kelly, D.J.; Psaltis, P.J.; Worthington, M.; Rajendram, A.; Kelly, D. R.; Nelson, A.J.; Zhang, Y.; Kuklik, P.; Brooks, A.G.; Worthley, S. G.; Faull, R. J.; Rao, M.; Edwards, J.; Saint, D.A.; Sanders, P. Short-term hypertension is associated with the development of atrial fibrillation substrate: A study in an ovine hypertensive model. Heart Rhythm, 2010, 7, 396-404.
14. Lau, D.H.; Mackenzie, L.; Kelly, D.J.; Psaltis, P.J.; Brooks, A.G.; Worthington, M.; Rajendram, A.; Kelly, D.R.; Zhang, Y.; Kuklik, P.; Nelson, A.J.; Wong, C.X.; Worthley, S.G.; Rao, M.; Faull, R.J.; Edwards, J.; Saint, D.A.; Sanders, P. Hypertension and atrial fibrillation: Evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm., 2010, 7, 1282-1290.
15. Abed, H.; et al. Heart Rhythm In press.
16. Maesen, B.; Nijs, J.; Maessen, J.; Allessie, M.; Schotten, U. Postoperative atrial fibrillation: a maze of mechanisms. Europace, 2012, 14, 159-174.
17. Spodick, D.H. Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. JAMA, 1976, 235, 39-41.
18. Libby, P. Molecular bases of the acute coronary syndromes. Circulation, 1995, 91, 2844-2850.
19. Koenig, W.; Sund, M.; Fröhlich, M.; Fischer, H.G.; Löwel, H.; Döring, A.; Hutchinson, W.L.; Pepys, M.B. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation, 1999, 99, 237-242.
20. Schwartz, C.J.; Valente, A.J.; Sprague, E.A.; Kelley, J.L.; Nerem, R. M. The pathogenesis of atherosclerosis: an overview. Clin. Cardiol., 1991, 14, I1-16.
21. Albert, C.M.; Ma, J.; Rifai, N.; Stampfer, M.J.; Ridker, P.M. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation, 2002, 105, 2595-2599.
22. Burke, A.P.; Tracy, R.P.; Kolodgie, F.; Malcom, G.T.; Zieske, A.; Kutys, R.; Pestaner, J.; Smialek, J.; Virmani, R. Elevated Creactive protein values and atherosclerosis in sudden coronary death: Association with different pathologies. Circulation, 2002, 105, 2019-2023.
23. Kaneko, H.; Anzai, T.; Naito, K.; Kohno, T.; Maekawa, Y.; Takahashi, T.; Kawamura, A.; Yoshikawa, T.; Ogawa, S. Role of ischemic preconditioning and inflammatory response in the development of malignant ventricular arrhythmias after reperfused STelevation myocardial infarction. J. Card. Fail, 2009, 15, 775-781.
24. Feldman, A.M.; McNamara, D. Myocarditis. N Engl J Med 2000, 343, 1388-98.
25. Group, J J.W. Guidelines for diagnosis and treatment of myocarditis (JCS 2009): Digest version. Circ. J., 2011, 75, 734-743.
26. Grün, S.; Schumm, J.; Greulich, S.; Wagner, A.; Schneider, S.; Bruder, O.; Kispert, E.-M.; Hill, S.; Ong, P.; Klingel, K.; Kandolf, R.; Sechtem, U.; Mahrholdt, H. Long-term follow-up of biopsyproven viral myocarditis: predictors of mortality and incomplete recovery. J. Am. College Cardiol., 2012, 59, 1604-1615.
27. Delcayre, C.; Swynghedauw, B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J. Mol. Cell. Cardiol., 2002, 34, 1577-1584.
28. Pitt, B.; White, H.; Nicolau, J.; Martinez, F.; Gheorghiade, M.; Aschermann, M.; van Veldhuisen, D.J.; Zannad, F.; Krum, H.; Mukherjee, R.; Vincent, J. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am. Coll. Cardiol., 2005, 46, 425-431.
29. Pitt, B.; Zannad, F.; Remme, W.J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med., 1999, 341, 709-717.
30. Dabrowski, R.; Borowiec, A.; Smolis-Bak, E.; Kowalik, I.; Sosnowski, C.; Kraska, A.; Kazimierska, B.; Wozniak, J.; Zareba, W.; Szwed, H. Effect of combined spironolactone--blocker $\pm$ enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am. J. Cardiol., 2010, 106, 1609-1614.
31. Walker, B.R. Glucocorticoids and cardiovascular disease. Eur. J. Endocrinol., 2007, 157, 545-559.
32. Shiroshita-Takeshita, A.; Brundel, B.J.J.M.; Lavoie, J.; Nattel, S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc. Res., 2006, 69, 865-875.
33. Goldstein, R.N.; Ryu, K.; Khrestian, C.; Wagoner, D.R.V.; Waldo, A.L. Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model. J. Cardiovasc. Electrophysiol., 2008, 19, 74-81.
34. Chung, M.K.; Martin, D.O.; Sprecher, D.; Wazni, O.; Kanderian, A.; Carnes, C.A.; Bauer, J.A.; Tchou, P.J.; Niebauer, M.J.; Natale, A.; Wagoner, D. R. V. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation, 2001, 104, 2886-2891.
35. Aviles, R.J.; Martin, D.O.; Apperson-Hansen, C.; Houghtaling, P.L.; Rautaharju, P.; Kronmal, R.A.; Tracy, R.P.; Wagoner, D.R.V.; Psaty, B.M.; Lauer, M. S.; Chung, M. K. Inflammation as a risk factor for atrial fibrillation. Circulation, 2003, 108, 3006-3010.
36. Abdelhadi, R.H.; Gurm, H.S.; Wagoner, D.R.V.; Chung, M.K. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am. J. Cardiol., 2004, 93, 1176-1178.
37. Anselmi, A.; Possati, G.; Gaudino, M. Postoperative inflammatory reaction and atrial fibrillation: Simple correlation or causation? Ann. Thorac. Surg., 2009, 88, 326-333.
38. Ho, K. M.; Tan, J. A. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: A dose-response meta-analysis. Circulation 2009, 119, 1853-66.
39. Hooft, C.S. van der; Heeringa, J.; Herpen, G. van; Kors, J.A.; Kingma, J. H.; Stricker, B. H. C. Drug-induced atrial fibrillation. J. Am. College Cardiol., 2004, 44, 2117-2124.
40. Hooft, C.S. van der; Heeringa, J.; Brusselle, G.G.; Hofman, A.; Witteman, J.C.M.; Kingma, J. H.; Sturkenboom, M.C.J.M.; Stricker, B. H. C. Corticosteroids and the risk of atrial fibrillation. Arch. Intern. Med., 2006, 166, 1016-1020.
41. Fujimoto, S.; Kondoh, H.; Yamamoto, Y.; Hisanaga, S.; Tanaka, K. Holter electrocardiogram monitoring in nephrotic patients during methylprednisolone pulse therapy. Am. J. Nephrol., 1990, 10, 231-236.
42. Caterina, R.D.; Ruigómez, A.; Rodríguez, L.A.G. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch. Intern. Med., 2010, 170, 1450-1455.
43. Yoon, M.S.; Goel, B. G.; Han, J. Effects of methylprednisolone on ventricular arrhythmias during acute myocardial ischaemia. Cardiovasc. Res., 1979, 13, 58-61.
44. Strain, J.E.; Grose, R.M.; Factor, S.M.; Fisher, J.D. Results of endomyocardial biopsy in patients with spontaneous ventricular tachycardia but without apparent structural heart disease. Circulation, 1983, 68, 1171-1181.
45. Mason, J.W.; O'Connell, J.B.; Herskowitz, A.; Rose, N.R.; McManus, B.M.; Billingham, M. E.; Moon, T. E. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N. Engl. J. Med., 1995, 333, 269-275.
46. Cooper, L.T.; Berry, G.J.; Shabetai, R. Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N. Engl. J. Med., 1997, 336, 1860-1866.
47. Kawano, S.; Kato, J.; Kawano, N.; Yoshimura, Y.; Masuyama, H.; Fukunaga, T.; Sato, Y.; Maruyama, H.; Mihara, K.; Ueda, A.; Toyoda, K.; Imamura, T.; Kitamura, K. Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period. Intern. Med., 2011, 50, 975-981.
48. Banba, K.; Kusano, K.F.; Nakamura, K.; Morita, H.; Ogawa, A.; Ohtsuka, F.; Ogo, K. O.; Nishii, N.; Watanabe, A.; Nagase, S.; Sakuragi, S.; Ohe, T. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm., 2007, 4, 1292-1299.
49. Yodogawa, K.; Seino, Y.; Ohara, T.; Takayama, H.; Katoh, T.; Mizuno, K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann. Noninvasive. Electrocardiol., 2011, 16, 140-147.
50. Seferovi, P.M.; Risti, A.D.; Maksimovi, R.; Simeunovi, D. S.; Risti, G. G.; Radovanovi, G.; Seferovi, D.; Maisch, B.; Matucci-Cerinic, M. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology, (Oxford) 2006, 45 (Suppl 4), iv39-42.
51. Catella-Lawson, F.; McAdam, B.; Morrison, B. W.; Kapoor, S.; Kujubu, D.; Antes, L.; Lasseter, K. C.; Quan, H.; Gertz, B. J.; FitzGerald, G.A. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther., 1999, 289, 735-741.
52. Hla, T.; Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA, 1992, 89, 7384-7388.
53. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M.C.; Kvien, T.K.; Schnitzer, T. J.; Group, V.S. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 2000, 343, 1520-1528, 2 p following 1528.
54. Silverstein, F.E.; Faich, G.; Goldstein, J.L.; Simon, L.S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N.M.; Stenson, W. F.; Burr, A.M.; Zhao, W.W.; Kent, J.D.; Lefkowith, J.B.; Verburg, K. M.; Geis, G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, 284, 1247-1255.
55. Kearney, P.M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J.R.; Patrono, C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 2006, 332, 1302-1308.
56. Zhang, J.; Ding, E.L.; Song, Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA, 2006, 296, 1619-1632.
57. Schmidt, M.; Christiansen, C. F.; Mehnert, F.; Rothman, K.J.; Sørensen, H.T. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ, 2011, 343, d3450.
58. Bäck, M.; Yin, L.; Ingelsson, E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur. Heart J., 2012, 33, 1928-1933.
59. Mathew, J.P.; Fontes, M. L.; Tudor, I.C.; Ramsay, J.; Duke, P.; Mazer, C.D.; Barash, P. G.; Hsu, P. H.; Mangano, D. T.; Research, I. of the I.; Foundation, E.; Group, M. S. of P. I. R. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA, 2004, 291, 1720-1729.
60. Cheruku, K.K.; Ghani, A.; Ahmad, F.; Pappas, P.; Silverman, P. R.; Zelinger, A.; Silver, M. A. Efficacy of nonsteroidal antiinflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. Prev. Cardiol., 2004, 7, 13-18.
61. Horbach, S. J.; Lopes, R.D.; Guaragna, J.C.V. Da C.; Martini, F.; Mehta, R.H.; Petracco, J. B.; Bodanese, L.C.; Filho, A.C.; Cirenza, C.; Paola, A.A.V. de; Investigators, N. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am. J. Med., 2011, 124, 1036-1042.
62. Mehta, R.H.; Starr, A.Z.; Lopes, R.D.; Hochman, J.S.; Widimsky, P.; Pieper, K.S.; Armstrong, P.W.; Granger, C.B.; Investigators, A. A. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA, 2009, 301, 1779-1789.
63. Hochberg, M.C. COX-2: Where are we in 2003?-Be strong and resolute: Continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients. Arthritis Res. Ther., 2003, 5, 28-31.
64. Bannwarth, B. Do selective cyclo-oxygenase-2 inhibitors have a future? Drug Saf., 2005, 28, 183-189.
65. Hochman, J. S.; Shah, N. R. What price pain relief? Circulation, 2006, 113, 2868-2870.
66. Graham, D.J. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA, 2006, 296, 1653-1656.
67. McGettigan, P.; Henry, D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med., 2011, 8, e1001098.
68. Kaufman, M. Celebrex trial halted after finding of heart risk: FDA chief urges patients to ask about alternatives. Washington Post.
69. Graham, D.J.; Campen, D.; Hui, R.; Spence, M.; Cheetham, C.; Levy, G.; Shoor, S.; Ray, W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet, 2005, 365, 475-481.
70. Maisch, B.; Seferovi, P.M.; Risti, A.D.; Erbel, R.; Rienmüller, R.; Adler, Y.; Tomkowski, W.Z.; Thiene, G.; Yacoub, M.H.; Diagnosis, T.F. on the; Cardiology, M. of P. D. of the E. S. of Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur. Heart J., 2004, 25, 587-610.
71. Troughton, R.W.; Asher, C.R.; Klein, A.L. Pericarditis. Lancet, 2004, 363, 717-27.
72. Lotrionte, M.; Biondi-Zoccai, G.; Imazio, M.; Castagno, D.; Moretti, C.; Abbate, A.; Agostoni, P.; Brucato, A. L.; Pasquale, P. D.; Raatikka, M.; Sangiorgi, G.; Laudito, A.; Sheiban, I.; Gaita, F. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am. Heart. J., 2010, 160, 662-670.
73. Imazio, M.; Bobbio, M.; Cecchi, E.; Demarie, D.; Demichelis, B.; Pomari, F.; Moratti, M.; Gaschino, G.; Giammaria, M.; Ghisio, A.; Belli, R.; Trinchero, R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation, 2005, 112, 2012-6.
74. Imazio, M.; Bobbio, M.; Cecchi, E.; Demarie, D.; Pomari, F.; Moratti, M.; Ghisio, A.; Belli, R.; Trinchero, R. Colchicine as firstchoice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch. Intern. Med., 2005, 165, 1987-1991.
75. Imazio, M.; Trinchero, R.; Brucato, A.; Rovere, M. E.; Gandino, A.; Cemin, R.; Ferrua, S.; Maestroni, S.; Zingarelli, E.; Barosi, A.; Simon, C.; Sansone, F.; Patrini, D.; Vitali, E.; Ferrazzi, P.; Spodick, D. H.; Adler, Y. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur. Heart J., 2010, 31, 2749-2754.
76. Imazio, M.; Brucato, A.; Ferrazzi, P.; Rovere, M. E.; Gandino, A.; Cemin, R.; Ferrua, S.; Belli, R.; Maestroni, S.; Simon, C.; Zingarelli, E.; Barosi, A.; Sansone, F.; Patrini, D.; Vitali, E.; Trinchero, R.; Spodick, D. H.; Adler, Y.; Investigators, C. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation, 2011, 124, 2290-2295.
77. Association, E.H.R.; Surgery, E. A. for C.-T.; Camm, A. J.; Kirchhof, P.; Lip, G.Y.H.; Schotten, U.; Savelieva, I.; Ernst, S.; Gelder, I.C.V.; Al-Attar, N.; Hindricks, G.; Prendergast, B.; Heidbuchel, H.; Alfieri, O.; Angelini, A.; Atar, D.; Colonna, P.; Caterina, R. D.; Sutter, J. D.; Goette, A.; Gorenek, B.; Heldal, M.; Hohloser, S. H.; Kolh, P.; Heuzey, J.-Y. L.; Ponikowski, P.; Rutten, F. H. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J., 2010, 31, 2369-2429.
78. Calkins, H.; Kuck, K. H.; Cappato, R.; Brugada, J.; Camm, A. J.; Chen, S.-A.; Crijns, H. J. G.; Damiano, R. J., Jr; Davies, D. W.; DiMarco, J.; Edgerton, J.; Ellenbogen, K.; Ezekowitz, M. D.; Haines, D. E.; Haissaguerre, M.; Hindricks, G.; Iesaka, Y.; Jackman, W.; Jalife, J.; Jais, P.; Kalman, J.; Keane, D.; Kim, Y.-H.; Kirchhof, P.; Klein, G.; Kottkamp, H.; Kumagai, K.; Lindsay, B. D.; Mansour, M.; Marchlinski, F. E.; McCarthy, P.M.; Mont, J. L.; Morady, F.; Nademanee, K.; Nakagawa, H.; Natale, A.; Nattel, S.; Packer, D.L.; Pappone, C.; Prystowsky, E.; Raviele, A.; Reddy, V.; Ruskin, J.N.; Shemin, R.J.; Tsao, H.-M.; Wilber, D. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace, 2012, 14, 528-606.
79. Koyama, T.; Tada, H.; Sekiguchi, Y.; Arimoto, T.; Yamasaki, H.; Kuroki, K.; Machino, T.; Tajiri, K.; Zhu, X. D.; Kanemoto-Igarashi, M.; Sugiyasu, A.; Kuga, K.; Nakata, Y.; Aonuma, K. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J. Am. Coll. Cardiol., 2010, 56, 1463-1472.
80. Deftereos, S.; Giannopoulos, G.; Kossyvakis, C.; Efremidis, M.; Panagopoulou, V.; Kaoukis, A.; Raisakis, K.; Bouras, G.; Angelidis, C.; Theodorakis, A.; Driva, M.; Doudoumis, K.; Pyrgakis, V.; Stefanadis, C. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J. Am. Coll. Cardiol., 2012, 60, 1790-1796.